🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Shadi Chamseddine

The University of Texas MD Anderson Cancer Center

ORCID: 0000-0001-7715-0689

Also affiliated with Wayne State University

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile
0Author DataRank

Indexed papers

0in pilot corpus
datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 8 papers. Top paper: “Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients”.

Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients

Oncotarget(2022)10.18632/oncotarget.28322
N/A
0.434DataRank · unranked
17 citations

Dan G. Duda, Muhammad O. Awiwi, Sunyoung S. Lee, Lina Altameemi, Lianchun Xiao +13 more

Circulating Galectin-3: A Prognostic Biomarker in Hepatocellular Carcinoma

Journal of Immunotherapy and Precision Oncology(2024)10.36401/jipo-24-6
N/A
0.330DataRank · unranked
8 citations

Betül Gök Yavuz, Yehia I. Mohamed, Sunyoung S. Lee, James C. Yao, Zishuo Ian Hu +13 more

Reproducible safety and efficacy of durvalumab with or without tremelimumab for hepatocellular carcinoma in clinical practice: Results of the DT-real study

JHEP Reports(2025)10.1016/j.jhepr.2025.101685
N/A
0.165DataRank · unranked
2 citations

Tiziana Pressiani, Naoshi Nishida, Shadi Chamseddine, Ashwini Arvind, Michael Li +36 more

Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.03.05.531188
N/A
0DataRank · unranked
5 citations

Yahui Zhu, Maiya Lee, Albert Nguyen, Nicolas T. Ryujin, Jian Yu Huang +7 more

Circulating tumor DNA (ctDNA) as a biomarker of response to therapy in advanced Hepatocellular carcinoma treated with Nivolumab

Cancer Biomarkers(2024)10.3233/cbm-230431
N/A
0DataRank · unranked
12 citations

Sunyoung S. Lee, Tarık Demir, Shadi Chamseddine, Zishuo Ian Hu, Lianchun Xiao +17 more

Efficacy and safety of atezolizumab/bevacizumab in patients with HCC after prior systemic therapy: A global, observational study

Hepatology Communications(2023)10.1097/hc9.0000000000000302
N/A
0DataRank · unranked
11 citations

Bernhard Scheiner, Antonio D ́Alessio, Claudia Angela Maria Fulgenzi, Martin Schönlein, Lorenz Kocheise +31 more

Plasma Growth Hormone as a Prognostic Biomarker to Durvalumab and Tremelimumab in Patients with Advanced Hepatocellular Carcinoma

Journal of Hepatocellular Carcinoma(2024)10.2147/jhc.s452564
N/A
0DataRank · unranked
2 citations

Michael LaPelusa, Lianchun Xiao, Yehia I. Mohamed, Sunyoung Lee, Zishuo Hu +8 more

Angiotensin II receptor inhibition ameliorates liver fibrosis and enhances hepatocellular carcinoma infiltration by effector T cells

Proceedings of the National Academy of Sciences(2023)10.1073/pnas.2300706120
N/A
0DataRank · unranked
46 citations

Yahui Zhu, Maiya Lee, Albert Nguyen, Nicolas T. Ryujin, Jian Yu Huang +8 more